A5012693904- PI3K/AKT/mTOR signaling in cancer
- Angiogenesis and VEGF in Cancer
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Platelet Disorders and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Melanoma and MAPK Pathways
- Cancer Immunotherapy and Biomarkers
- Chronic Lymphocytic Leukemia Research
- Gastric Cancer Management and Outcomes
- Cancer Cells and Metastasis
- Acute Lymphoblastic Leukemia research
- Cancer Treatment and Pharmacology
- Nanoparticle-Based Drug Delivery
- Lymphatic System and Diseases
- Lymphoma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Economic and Financial Impacts of Cancer
- Gastrointestinal Tumor Research and Treatment
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Neuroendocrine Tumor Research Advances
- Glycosylation and Glycoproteins Research
- Cytokine Signaling Pathways and Interactions
University of Zurich
2021-2025
University Hospital of Zurich
1994-2025
University Hospital of Basel
2013-2024
University Hospital of Geneva
2024
Dr. A. Ramachandran's Diabetes Hospitals
2024
Kantonsspital Baselland
2018-2023
Swissmedic
2023
University of Basel
2008-2022
Psychiatry Baselland
2020
Friedrich Miescher Institute
2015-2016
<h3>Background</h3> Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) have been recently approved for treatment of patients with metastatic melanoma non-small lung cancer (NSCLC). Despite important clinical benefits, these therapies are associated a diverse spectrum immune-related adverse events (irAEs) that typically transient, but occasionally severe or even fatal. <h3>Case presentation</h3> This autopsy case...
Abstract The presence of circulating tumor cell (CTC) clusters is associated with disease progression and reduced survival in a variety cancer types. In breast cancer, preclinical studies showed that inhibitors the Na + /K ATPase suppress CTC block metastasis. Here we conducted prospective, open-label, proof-of-concept study women metastatic where primary objective was to determine whether treatment inhibitor digoxin could reduce mean cluster size. An analysis nine patients treated daily...
Strong overexpression of glucagonlike peptide-1 (GLP-1) receptors in human insulinoma provides an attractive target for imaging. The first clinical trials demonstrated that GLP-1 receptor SPECT/CT using [Lys<sup>40</sup>(Ahx [6-aminohexanoic acid]-DOTA-<sup>111</sup>In)NH<sub>2</sub>]-exendin-4 can localize hardly detectable insulinomas. However, [Lys<sup>40</sup>(Ahx-DOTA-<sup>111</sup>In)NH<sub>2</sub>]-exendin-4 imaging has drawbacks related to the use <sup>111</sup>In it is costly and...
Abstract Purpose: Activation of the PI3K/mTOR signaling pathway is recurrent in different lymphoma types, and pharmacologic inhibition has shown activity patients. Here, we extensively characterized vitro vivo mechanism action PQR309 (bimiralisib), a novel oral selective dual inhibitor under clinical evaluation, preclinical models. Experimental Design: This study included screening on large panel cell lines, both as single agent combination, validation experiments models primary cells,...
Treatment of platelets with human leukocyte elastase causes a rapid loss in response to von Willebrand factor and biphasic thrombin, first then more slowly. The phase corresponds cleavage 45‐kDa glycopeptide from the extracellular end membrane glycoprotein GPIb. Longer treatment removes 80‐kDa 90‐kDa glycopeptides corresponding major part GPV. species could be obtained by glycocalicin, proteolytic product Polyclonal rabit antibodies against purified had same effect on action thrombin as GPIb...
Angiogenesis is a key process in tumor progression. By binding VEGF, VEGF receptor-2 (VEGFR2) main signaling transducer tumor-associated angiogenesis. Accordingly, therapeutic approaches against the VEGF/VEGFR2 axis have been designed. However, an efficient and specific chemotherapeutic targeting of endothelial cells has not yet achieved.We employed anti-VEGFR2 antibodies covalently linked to pegylated liposomal doxorubicin (PLD) specifically ablate Rip1Tag2 mouse model insulinoma, MMTV-PyMT...
Advanced triple negative breast cancer (TNBC) is an aggressive, but initially chemo-sensitive disease. The prognosis poor and more than three quarters of patients experience progression 12 months after the initiation conventional first-line chemotherapy. Approximately two thirds TNBC express epidermal growth factor receptor 1 (EGFR). We have developed anti-EGFR targeted nanocontainer drug by inserting antibody fragments into membrane pegylated liposomes (anti-EGFR-ILs-dox). payload consists...
Spatial proteomics technologies have transformed our understanding of complex tissue architectures by enabling simultaneous analysis multiple molecular markers and their spatial organization. The high dimensionality these data, varying marker combinations across experiments heterogeneous study designs pose unique challenges for computational analysis. Here, we present Virtual Tissues (VirTues), a foundation model framework biological tissues that operates the molecular, cellular scale....
Swiss healthcare institutions conducted only urgent procedures during the COVID-19 lockdown, potentially leading to a lack of care for other severe diseases, such as cancer. We examined effects pandemic on cancer stage distribution and time between diagnosis treatment initiation using population-based registry data. The study was based data cantons Zurich Zug from 2018 2021. Cancer analysed descriptively with Pearson's Chi-squared test. Time determined in days by fitting Quasipoisson...
Abstract Purpose: Although metabolic changes make diagnosis of insulinoma relatively easy, surgical removal is hampered by difficulties in locating it, and there no efficient treatment for malignant insulinoma. We have previously shown that the high density glucagon-like peptide-1 receptors (GLP-1R) human cells provides an attractive target molecular imaging internal radiotherapy. In this study, we investigated therapeutic potential [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4, 111In-labeled agonist...